Vor Biopharma Files 8-K on Officer/Director Changes & Votes
Ticker: VOR · Form: 8-K · Filed: May 28, 2024 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, corporate-action
Related Tickers: VORB
TL;DR
Vor Bio's leadership team is changing, with new officers and directors elected and some departing.
AI Summary
Vor Biopharma Inc. filed an 8-K on May 28, 2024, reporting events as of May 23, 2024. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key personnel and governance can signal underlying issues or strategic realignments that may affect the company's future performance.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- May 23, 2024 (date) — Earliest event reported
- May 28, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Principal executive offices
FAQ
What specific reasons were given for the departure of any directors or officers?
The filing indicates the 'Departure of Directors or Certain Officers' as an item reported, but does not provide specific reasons within the provided text.
Who were the newly elected directors or appointed officers?
The filing lists 'Election of Directors' and 'Appointment of Certain Officers' as reported items, but the names of the individuals are not detailed in the provided text.
Were there any specific compensatory arrangements disclosed for the officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as a reported item, but the details of these arrangements are not included in the provided text.
What matters were submitted to a vote of security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' was reported, but the specific matters are not detailed in the provided text.
What financial statements or exhibits are included with this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but their specific content is not detailed in the provided text.
Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-05-28 16:54:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
Filing Documents
- d829841d8k.htm (8-K) — 36KB
- d829841dex101.htm (EX-10.1) — 166KB
- 0001193125-24-148151.txt ( ) — 373KB
- vor-20240523.xsd (EX-101.SCH) — 3KB
- vor-20240523_lab.xml (EX-101.LAB) — 19KB
- vor-20240523_pre.xml (EX-101.PRE) — 12KB
- d829841d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. By: /s/ Robert Ang Robert Ang Chief Executive Officer Date: May 28, 2024